Who asks: the clinical safety physician for study CBP-TLV-301 at Calder Bay Pharma, a fictional company.
Why: a subject in a blinded US trial has died of acute liver failure, and the shortest reporting clocks in drug safety have started.
The data: the follow-up SAE form on the left and the Teluvant Investigator's Brochure (Reference, then Products).
What done looks like: a worksheet with the seriousness criteria, expectedness against the Investigator's Brochure, what the blind decides, the 7-day and complete report due dates, what the US IND safety report needs, and who stays blinded.
A case study in six steps on one follow-up SAE form. It brings together expectedness, unblinding and the shortest clocks in drug safety.